Objective: To identify the gene mutation of tubular aggregate myopathy (TAM) and gain mechanistic insight into the pathogenesis of the disorder.
Tubular aggregate myopathy (TAM) is a disorder characterized by slowly progressive muscle weakness and atrophy. The pathologic feature is the appearance of tubular aggregates in skeletal muscle. The tubular aggregates are a subsarcolemmal accumulation of granular materials that is stained bright purple with Gomori trichrome staining and exhibits accumulation of regular arrays of membrane tubules under an electron microscope. 1 The tubular aggregates are thought to originate from sarcoplasmic reticulum (SR) 2 ; however, the exact mechanism leading to their formation and the significance on muscle fibers remain unknown. 3 Recently, several mutations in stromal interaction molecule 1 (STIM1), a Ca 21 sensor in SR, have been identified in dominantly inherited TAM (OMIM #160565). [4] [5] [6] All mutations demonstrated so far have been missense mutations located in the EF hand of the N-terminal luminal region and are thought to disrupt the Ca 21 binding to this region. In this article, we present a dominant TAM family in whom a novel insertion mutation was identified in the C-terminal inhibitory domain (CTID) located in the cytoplasmic region of STIM1 and investigate the functional significance of the mutation using cultured cells.
METHODS Standard protocol approvals, registrations, and patient consents. This study was approved by the institutional review board of Teikyo University. The patients gave written informed consent to participate in this study.
Histologic analyses. Muscle specimens were taken from the biceps brachii muscle. Standard techniques were used for the preparation of frozen sections; hematoxylin and eosin (H&E), Gomori trichrome, NADH-tetrazolium reductase (TR), and ATPase staining; and immunofluorescent and electron microscopic analysis. Mouse monoclonal antibody against STIM1 and rabbit polyclonal antibody against ORAI were obtained from BD Biosciences (Franklin Lakes, NJ) and Merck (Darmstadt, Germany), respectively.
Genetic analysis. Genomic DNA samples were extracted from peripheral blood leukocytes. Exonic sequences were enriched using a SureSelect v51UTRs kit (Agilent, Santa Clara, CA) and subjected to nucleotide sequence analysis using a Hiseq2500 platform (Illumina, San Diego, CA). Burrows-Wheeler Aligner and Samtools were used with default settings for the alignment of raw reads and variant detection. The protein-altering variants in STIM1 and ORAI1 were filtered by excluding those present in 600 healthy Japanese controls. Direct nucleotide sequence analysis was performed using an ABI 3100 Genetic Analyzer (Thermo Fisher Scientific, Waltham, MA). Messenger RNA (mRNA) was extracted from muscle biopsy specimen using RNeasy Fibrous tissue mini kit (Qiagen, Hilden, Germany) and amplified by reverse transcriptase (RT)-PCR with SuperScript (Thermo Fisher Scientific).
Expression study of STIM1 in C2C12 myoblasts. Expression plasmid encoding human STIM1 complementary DNA was purchased from OriGene and the mutation c.1450_1451insGA was introduced with a KOD-Plus mutagenesis kit (Toyobo, Osaka, Japan). Two days after transfection using Effectene (Qiagen), C2C12 myoblasts were labeled with anti-STIM1, Alexa Fluor 594-conjugated phalloidin (Thermo Fisher Scientific) and 49,6-diamidino-2-phenylindole (DAPI). The images were obtained using an FSX100 fluorescence microscope (Olympus, Tokyo, Japan). Statistical differences were evaluated by the t test.
Measurement of changes in intracellular Ca

21
concentration. Ca 21 measurements were carried out as previously described 7 with minor modifications. HEK293 cells were cotransfected with plasmids expressing STIM1 and pIRES2-mCherry. Transfection was carried out using X-tremeGENE HP transfection reagent (Roche, Basel, Switzerland). Transfected HEK293 cells were trypsinized and seeded onto poly-L-lysine-coated glass coverslips the next day. Ca 21 imaging was performed 42-48 hours after transfection. HEK293 cells on coverslips were loaded with Fura-2 by incubation in Dulbecco's modified Eagle medium containing 5 mM Fura-2/AM (Dojindo, Kumamoto, Japan) at 37°C for 40 minutes. The coverslips were then placed in a perfusion chamber mounted on the stage of a microscope (Axioobserver Z1; Carl Zeiss, Oberkochen, Germany). Transfected cells were identified by the detection of fluorescence from mCherry. Fura-2 fluorescence images recorded at 10-second intervals were analyzed using Physiology software (Carl Zeiss).
RESULTS Clinical data. A 42-year-old Japanese man presented with difficulty walking. He first noticed slight difficulty walking when he was 37 years old. At the age of 40, running and climbing stairs became difficult. His mother also had difficulty walking and was in a wheelchair when she was 40 years old. His parents were not consanguineous. On neurologic examination, pupils and ocular movement were normal. The temporalis and masseter muscles on both sides were atrophic. Muscle atrophy and weakness was evident in all 4 limbs, and the bilateral triceps surae muscles were most prominently affected ( figure  1A ). The paraspinal muscles were also atrophic and he had winged scapulae (figure 1B). His gait was lordotic. Ankle joint contracture was observed bilaterally. He did not exhibit myalgia, cramps, scoliosis, rigid spine, or symptoms suggesting Stormorken syndrome, including miosis, thrombocytopenia, asplenia, or ichthyosis. 8 He had no history of repetitive infections indicative of immunodeficiency. 9 Blood cell counts and routine blood biochemistry were normal, except serum creatine kinase was elevated to 798 IU/L (normal range ,150). Needle EMG showed chronic myopathic changes. Muscle MRI revealed disseminated high-intensity areas on T1-weighted images in the quadriceps femoris, triceps surae, and paraspinal muscles, indicating fatty replacement in these muscles ( figure 1C ).
Pathologic findings. H&E staining demonstrated increased variability of muscle fiber diameter and occasional centrally nucleated myofibers. In addition, many fibers showed irregularly shaped dark red staining ( figure 1D ). These dark red accumulations were stained intense blue by NADH-TR ( figure 1E ) and bright purple with Gomori trichrome staining (figure 1F), indicating that these are tubular aggregates. A serial section stained with ATPase (pH 4.6) further demonstrated that the tubular aggregates were in type 2 fibers (figure 1G). Electron microscopic analysis revealed that some areas in the myofiber were replaced by numerous tubular structures (figure 1H) and that each tubule was arranged in a honeycomb-like structure that showed double-walled membranes at higher magnification (figure 1H, inset).
Genetic analysis and localization of STIM1 in skeletal muscle. The clinical and microscopic findings characteristic of TAM prompted us to perform genetic analysis. Exome sequence analysis and subsequent Sanger sequencing of the proband revealed a novel heterozygous insertion mutation, c.1450_1451insGA (p.Ile484ArgfsX21), in exon 7 of STIM1 (figure 2A). The same mutation was identified in his mother but not in healthy family members (figure 2B). The amino acid 484 resides in the CTID located in the cytoplasmic region of STIM1 ( figure 2C) . To assess the localization of STIM1 in the skeletal muscle of the patient, we performed immunofluorescent microscopic analysis. The immunolabeling of STIM1 and ORAI1, a calcium channel in plasma membrane, colocalized to the tubular aggregates visualized by Gomori trichrome staining (figure 2D), which is consistent with previous reports. 4, 7 Because premature termination codons often result in nonsense-mediated decay of mRNA, we analyzed mRNA transcript in the muscle biopsy specimen.
Sequencing of the RT-PCR product demonstrated that both wild-type and the c.1450_1451insGA mutant transcripts are present (figure 2E).
Expression of mutant STIM1 in C2C12 myoblasts. To investigate the functional significance of the c.1450_1451in-sGA mutation, we transfected C2C12 myoblasts with wild-type and mutant STIM1. Typically, wild-type STIM1 displayed diffuse distribution in C2C12 cells ( figure 3A) . In sharp contrast, mutant STIM1 concentrated intensely around nuclei and exhibited an aggregation-like appearance in shrunk cytoplasm ( figure 3A ). Counting cells with the diffuse vs aggregation-like localization of STIM1 confirmed that the majority of cells expressing wild-type STIM1 showed diffuse localization whereas most cells expressing mutant STIM1 exhibited an aggregationlike pattern (figure 3B). figure 3, C and D) . These results collectively suggest that the STIM1 mutation we found in this study causes dysregulated Ca 21 homeostasis.
Effects of
DISCUSSION In the present study, we described a family with dominant TAM with a novel frameshift mutation in the CTID of STIM1. Of note, the triceps surae muscles were most severely involved in our patient. This is in contrast to the previous reports of TAM, in which the proximal muscles were predominantly affected. 4, 5 In skeletal muscle, Ca 21 homeostasis is regulated by SOCE. In SOCE, STIM1 forms an oligomer upon the depletion of Ca 21 in SR and activates ORAI1 channels at sarcolemma, triggering extracellular Ca 21 entry. 10 All STIM1 mutations in TAM reported so far are missense mutations residing in the EF hand (EF1 and EF2 in figure 2B ), and this region is considered a hotspot. [4] [5] [6] These mutations are presumed to induce the constitutive activation of ORAI1 and cause excessive Ca 21 influx into muscle cells.
In contrast, a frameshift mutation, which creates a premature stop codon in the CTID located in the Cterminal cytoplasmic region of STIM1, was identified in our family (figure 2B). The CTID is known to interact with SOCE-associated regulatory factor (SARAF), a regulator of slow Ca 21 -dependent inactivation of OR-AI1. 11 Following the transfection of C2C12 myoblasts with the CTID mutant STIM1, aggregation-like signals of STIM1 were observed around the nuclei. The aggregation-like appearance is distinct from that in C2C12 myoblasts transfected with STIM1 harboring EF hand mutations, which exhibit numerous punctalike small clusters in cytoplasm. 4, 6 Furthermore, intracellular Ca 21 measurements revealed that the Ca 21 influx is significantly decreased in the cells transfected with the CTID mutant compared to the wild-type STIM1-transfected cells. This result is in marked contrast to the previous reports, in which increased Ca 21 influx caused by constitutive activation of SOCE was observed. 4, 7 The transcript of CTID mutant was present in the affected skeletal muscle of our patient, suggesting that nonsense-mediated mRNA decay is not induced. We speculate that the CTID mutant may inhibit the oligomer formation of STIM1 necessary to activate the ORAI1 channels, leading to the decreased intracellular Ca 21 influx. Alternatively, the STIM1 oligomer including the CTID mutant may not translocate properly to the subsarcolemma where the oligomer interacts with ORAI1, because the CTID mutant lacks the polybasic motif (K in figure 2C ) necessary for the STIM1 targeting to plasma membrane. 12 It is of particular interest to note that STIM2b, an alternatively spliced form of STIM2, converts STIM isoforms from an activator to an inhibitor of ORAI1. 13 Our findings provide further evidence that the dysregulation of Ca 21 homeostasis underlies the pathomechanism of TAM.
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